Testing a new treatment approach for relapsing multiple sclerosis

Plain-English translation of NCT05877963 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated September 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new dosing schedule for a medication called in people with relapsing multiple sclerosis (a type of MS where symptoms come and go). The study has three parts and will look at whether this treatment works well, how safe it is, and how the medication moves through your body. Researchers also want to see if the medication helps people who didn't have good results with similar treatments before.

Relapsing multiple sclerosis can be unpredictable and disabling, and some people don't respond well to existing treatments. This trial is testing whether a different dosing schedule of this medication might work better for patients and might help those who had problems tolerating similar drugs in the past.

Do you qualify?

You likely qualify if…

you have been diagnosed with relapsing multiple sclerosis using current diagnostic criteria
you are either treatment-naïve or have stopped a previous MS medication and waited the required time
you have a disability score of 5.5 or lower on the Expanded Disability Status Scale
you have been neurologically stable (no new symptoms or worsening) for more than 30 days before starting the study
if you can have children, you agree to use an acceptable form of birth control during the study and for 6 months after your last dose

You likely don't qualify if…

you have had a serious infusion reaction to anti-CD20 medications (a similar type of treatment) in the past
you have primary-progressive multiple sclerosis or inactive secondary-progressive multiple sclerosis
you have an active immune system disease (other than MS) or a condition that weakens your immune system
you have a current serious infection or a history of infections like tuberculosis or chronic hepatitis
you have received certain other medications in the past, including alemtuzumab, cyclophosphamide, cladribine, or ublituximab

What participation looks like

Depending on which part of the study you join, you would receive infusions of the medication (or placebo) at specific timepoints — typically on the first day, around day 15, and at week 24. Some participants will receive the active medication throughout, while others in one part of the study will receive placebo at one timepoint to help researchers understand how well the treatment works. You'll have regular visits for brain imaging and blood tests to measure how the medication is affecting your MS and how your body is processing it.

AI-generated summary from trial data · Sep 3, 2026 · Not medical advice

Trial locations(51 sites)

United States

TG Therapeutics Investigational Trial Site, Birmingham, Alabama

TG Therapeutics Investigational Trial Site, Cullman, Alabama

TG Therapeutics Investigational Trial Site, Orange, California

TG Investigational Site, Fort Collins, Colorado

TG Therapeutics Investigational Trial Site, Washington D.C., District of Columbia